Results 161 to 170 of about 212,526 (280)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, Volume 116, Issue 5, Page 522-534, May 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

New England Journal of Medicine, 2014
J. Woyach, R. Furman, Ta-Ming Liu, H. Ozer, M. Zapatka, A. Ruppert, L. Xue, Daniel Li, S. Steggerda, M. Versele, S. Dave, Jenny Zhang, A. S. Yilmaz, S. Jaglowski, K. Blum, A. Lozanski, G. Lozanski, D. James, J. Barrientos, P. Lichter, S. Stilgenbauer, J. Buggy, B. Chang, A. Johnson, J. Byrd   +24 more
semanticscholar   +1 more source

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real‐world study

Cancer, Volume 132, Issue 8, 15 April 2026.
Abstract Background Real‐world data are an essential complement to clinical trials. This is particularly true for chronic lymphocytic leukemia, where five first‐line options have never been directly compared. Methods The authors present the results of a national multicenter real‐world study focusing on treatment choices in frontline chronic lymphocytic
Arthur Coste, Nanthara Sritharan, Anne Lok, Cécile Tomowiak, Emmanuelle Ferrant, Aline Clavert, Damien Roos‐Weil, Florian Bouclet, Adrien Caillet, Carolyne Croizier, Nicolas Stocker, Emmanuelle Tchernonog, Pierre Feugier, Alberto Santagostino, Bénédicte Hivert, Anne‐Sophie Michallet, Sophie De Guibert, Diane Lara, Agathe Waultier‐Rascalou, Fatiha Merabet, Amandine Durand, Lucile Bussot, Kamel Laribi, Marie‐sarah Dilhuydy, Vincent Lévy, Anne Quinquenel   +25 more
wiley   +1 more source

BCR Engagement Induces Fas Resistance in Primary B Cells in the Absence of Functional Bruton’s Tyrosine Kinase [PDF]

, 2002
Joseph R. Tumang, Robert S. Negm, Laura A. Solt, Thomas J. Schneider, Thomas P. Colarusso, William D. Hastings, Robert T. Woodland, Thomas L. Rothstein   +7 more
openalex   +1 more source

Cutting Edge: Lack of Peripheral B Cells and Severe Agammaglobulinemia in Mice Simultaneously Lacking Bruton’s Tyrosine Kinase and the B Cell-Specific Transcriptional Coactivator OBF-1 [PDF]

, 2000
Daniel Schubart, Antonius Rolink, Karin Schubart, Patrick Matthias   +3 more
openalex   +1 more source

Challenges with Bruton’s Tyrosine Kinase Inhibitors Treatment [PDF]

Nahla A M Hamed
openalex   +1 more source

From phagocytosis to metaforosis: calcineurin's deadly role in innate processing of fungi [PDF]

, 2018
Armstrong-James, D, Bercusson, A, De Boer, L, Shah, A   +3 more
core   +3 more sources

Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity

, 2014
Xitao Li, Yingying Zuo, Guanghui Tang, Yan Wang, Yiqing Zhou, Xueying Wang, Tianlin Guo, Mengying Xia, Ning Ding, Zhengying Pan   +9 more
openalex   +1 more source

Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase

, 2015
Christopher R. Smith, Douglas R. Dougan, Mallareddy Komandla, Toufike Kanouni, Beverly Knight, J. David Lawson, M. Sabat, Ewan R. Taylor, Phong Vu, Corey Wyrick   +9 more
openalex   +2 more sources